Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
Japanese drugmaker Takeda (TYO: 4502) has signed an option agreement with China’s Ascentage Pharma (HKG: 6855) to enter into an exclusive license agreement for 14 June 2024
Avidity Biosciences, a biopharmaceutical company specializing in RNA therapeutics, has announced a public share offering, with the goal of raising $400 million. 14 June 2024
Kite, a Gilead Sciences company, has unveiled new analyses for Yescarta (axicabtagene ciloleucel) in relapsed/refractory large B-cell lymphoma (LBCL). 14 June 2024
The market for amyotrophic lateral sclerosis (ALS) across mature markets could reach $1.3 billion by 2029, up from $317 million in 2019, according to GlobalData 13 June 2024
US drugmaker AbbVie and China’s FutureGen Biopharmaceutical have announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treat 13 June 2024
Belgium’s UCB is sharing results from three studies supporting the value of Cimzia (certolizumab pegol) for women of childbearing age living with chronic immune 13 June 2024
One of the most important medical meetings in rheumatology is underway in Vienna, Austria, and leading drugmakers in the field have lifted the lid on data they 12 June 2024